Varivax (varicella virus vaccine live) / Merck (MSD) - LARVOL DELTA

Safety of Live Vaccines in Patients With Inflammatory Bowel Disease on Biologic Therapy: A Propensity Score Matched Analysis (ACG 2025) - "Biologic therapies included tumor necrosis factor inhibitors (infliximab, adalimumab), integrin antagonists (vedolizumab), interleukin-12/23 inhibitors (ustekinumab), interleukin-23 inhibitors (risankizumab, guselkumab), and Janus kinase inhibitors (tofacitinib, upadacitinib)... A total of 758 patients were included in each matched cohort. No significant increase in adverse events was observed in the vaccinated group compared to the unvaccinated group. Inpatient visits occurred in 8.7% vs 9.1% (risk ratio [RR] 0.95; 95% confidence interval [CI]: 0.55–1.65; p=0.866), and ED visits in 6.4% vs 8.3% (RR 0.78; 95% CI: 0.48–1.25; p=0.298)."

Clinical • CNS Disorders • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Measles • Mumps • Pneumonia • Respiratory Diseases • Rubella • Septic Shock • Ulcerative Colitis • Varicella Zoster • IL12A

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years (clinicaltrials.gov) - P3 | N=474 | Not yet recruiting | Sponsor: GC Biopharma Corp

Head-to-Head • New P3 trial • Infectious Disease • Varicella Zoster

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Varicella Zoster

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=900 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Trial completion date: May 2027 ➔ Aug 2027 | Trial primary completion date: May 2027 ➔ Aug 2027

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (clinicaltrials.gov) - P2 | N=76 | Completed | Sponsor: Memorial Sloan Kettering Cancer Center | Active, not recruiting ➔ Completed

Trial completion • Oncology

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=1080 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=1080 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=900 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=1840 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Varicella Zoster

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • Infectious Disease • Varicella Zoster

Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines (clinicaltrials.gov) - P3 | N=642 | Completed | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. | Enrolling by invitation ➔ Completed

Trial completion • Varicella Zoster

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=750 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Varicella Zoster

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (clinicaltrials.gov) - P3 | N=1196 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed | Trial completion date: May 2025 ➔ Dec 2024

Trial completion • Trial completion date • Infectious Disease • Meningococcal Infections • Pneumococcal Infections

CORAL: Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (clinicaltrials.gov) - P3 | N=2226 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Functional efficacy of nanoparticle conjugated P. vivax circumsporozoite protein subdomain vaccine (ASTMH 2024) - "Mice were immunized with different recombinant CSP subunits formulated with CpG-1018 as adjuvant and surface conjugated to PLGA nanoparticles and the immunogenicity was evaluated. NP conjugated rCSP subunit formulations induced high titer antibodies to the respective rCSP antigens that could recognize the native antigen on the sporozoite. Preliminary studies revealed that the antibodies produced by NP conjugated rPvCSP sub-domains showed inhibition of transgenic P. berghei sporozoites expressing PvCSP liver stage development in vitro ."

Clinical • Hepatology • Infectious Disease • Malaria

VE210. Hepatobiliary Surgery II (ACS-CLINCON 2024) - No abstract available

Surgery

Low Genetic Diversity of Plasmodium vivax Circumsporozoite Surface Protein in Clinical Isolates from Southern Thailand. (PubMed, Trop Med Infect Dis) - "This study underscores the limited diversity of VK210 variants of P. vivax populations in southern Thailand. These baseline findings facilitate monitoring for potential new parasite variants, aiding in the future control and management of P. vivax in the region."

Journal • Infectious Disease • Malaria

A two-dose viral-vectored Plasmodium vivax multistage vaccine confers durable protection and transmission-blockade in a pre-clinical study. (PubMed, Front Immunol) - "These findings provide proof-of-concept that the m8Δ/AAV1 vaccine platform is sufficiently versatile for P. vivax vaccine development. Future studies are needed to evaluate the safety, immunogenicity, vaccine efficacy, and synergistic effects on protection and transmission blockade in a non-human primate model for Phase I trials."

Journal • Preclinical • Viral vector • Infectious Disease • Malaria

Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol®) as adjuvant. (PubMed, Vaccine) - "Furthermore, mice that received the vaccine formulation were protected after the challenge with Plasmodium berghei sporozoites expressing CSP repeats from P. vivax sporozoites (Pb/Pv-VK210). In conclusion, in these non-clinical models, repeated dose administrations of the PvCSP-All epitopes vaccine adjuvanted with a Poly-ICLC were immunogenic, safe, and well tolerated."

Journal • Infectious Disease • Inflammation • Malaria

Longitudinal analysis of antibody responses to Plasmodium vivax sporozoite antigens following natural infection. (PubMed, PLoS Negl Trop Dis) - "The present study demonstrated the magnitude and longevity of serological responses to multiple PE antigens of P. vivax after natural infection. This knowledge could contribute to the design of an effective P. vivax vaccine."

Journal • Infectious Disease • Malaria